Medy-Tox메디톡스
086900 · KOSDAQ · ₩086900 · 메디톡스
₩63,900▼ ₩300 (0.47%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 61.9% | 57.9% | 60.8% | 60.5% | 64.8% | 57.3% |
| Operating margin | 6.9% | 6.9% | 8.9% | 7.8% | 23.9% | 18.7% |
| Net margin | 6.1% | 6.7% | 7.4% | 4.4% | 19.0% | 50.9% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +1.5% | +8.2% | +3.4% | +13.3% | +5.5% | — |
| Operating income growth | +2.0% | −16.4% | +17.5% | −62.9% | +35.3% | — |
| Net income growth | −7.7% | −2.1% | +73.8% | −73.6% | −60.7% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 3.7% | 3.6% | 3.6% | 2.2% | 8.9% | 23.6% |
| Return on assets | 1.8% | 2.6% | 2.6% | 1.6% | 6.2% | 16.1% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 50.8% | 28.1% | 30.7% | 28.9% | 37.5% | 43.1% |
| Net debt to equity | 19.7% | 5.7% | 4.2% | 10.4% | 22.8% | −10.4% |
| Current ratio | 103.4% | 148.2% | 158.7% | 131.4% | 99.9% | 149.1% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Medy-Tox / 메디톡스 / 086900 / KRX:086900
Source: KRX statistical information